SOUTH SAN FRANCISCO, Calif., Nov 10, 2010 (BUSINESS WIRE) -- Exelixis, Inc. (Nasdaq:EXEL) announced today the following upcoming investor events:

• Lazard Capital Markets Healthcare Conference: Michael M. Morrissey, PhD, the company's president and chief executive officer will present at the Lazard Capital Markets Healthcare Conference in New York at 11:25 a.m. EST / 8:25 a.m. PST on Tuesday, November 16, 2010. He will discuss the company's development pipeline and provide a general business update.
• EORTC-NCI-AACR Symposium: A conference call to review the data from the six posters presented at the EORTC-NCI-AACR Symposium on the company's randomized discontinuation trial of XL184 will be held on Thursday, November 18 at 7:30 a.m. EST / 4:30 a.m. PST. During the conference call, Exelixis management will provide an overview of the data presented at the meeting, and Dr. Matthew Smith of Massachusetts General Hospital will provide an update on the castration-resistant prostate cancer cohort. An audio replay will be available until 11:59 p.m ET/ 8:59 p.m. PT on December 4, 2010. Access numbers for the replay are: 1-888-286-8010 (domestic) and 1-617-801-6888 (international), and the passcode is 94605525.
• Piper Jaffray 22^nd Annual "Unplugged" Health Care Conference: Dr. Morrissey will present at Piper Jaffray's 22^nd Annual "Unplugged" Health Care Conference in New York at 8:00 a.m. EST / 5:00 a.m. PST on Tuesday, November 30, 2010. He will discuss the XL184 data presented at the EORTC-NCI-AACR Symposium and the company's development pipeline, and will provide a general business update.
• Exelixis Annual R&D Day: The company will host its Annual R&D Day on Thursday, December 2, 2010 from 10:00 a.m. EST / 7:00 a.m. PST until 2:30 p.m. EST / 11:30 a.m. PST. During this event, key clinical investigators for the company's randomized discontinuation trial of XL184 will discuss the data presented at the EORTC-NCI-AACR Symposium. In addition, Exelixis management will outline the development priorities for XL184, discuss the company's development and corporate strategy, and provide a general business update.

Each of these investor events will be webcast and may be accessed on the Event Calendar page under Investors at www.exelixis.com for a period of 30 days following the date of the event.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer. The company is leveraging its biological expertise and integrated research and development capabilities to generate a pipeline of development compounds with significant therapeutic and commercial potential for the treatment of cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, sanofi-aventis, GlaxoSmithKline, Genentech (a wholly owned member of the Roche Group), Boehringer Ingelheim, and Daiichi-Sankyo. For more information, please visit the company's web site at www.exelixis.com.

SOURCE: Exelixis, Inc.

Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President,
Investor Relations
and Corporate Communications
cbutler@exelixis.com
DeDe Sheel, 650-837-8231
Associate Director,
Investor Relations
dsheel@exelixis.com